Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer

NCT03238196 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Erdafitinib
DRUG: Palbociclib
DRUG: Fulvestrant

Sponsor

Vanderbilt-Ingram Cancer Center

Collaborators

[object Object]